Ru-inn Lin

Dalin, KHQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal.

Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal.

Journal: Cancer cell international

Published: June 01, 2024

Wogonin Inhibits Ovarian Cancer by Activating the AMPK-TET2-5hmC Axis.

Wogonin Inhibits Ovarian Cancer by Activating the AMPK-TET2-5hmC Axis.

Journal: Molecular carcinogenesis

Published: April 24, 2024

Targeting PADI2 as a potential therapeutic strategy against metastasis in oral cancer via suppressing EMT-mediated migration and invasion and CCL3/5-induced angiogenesis.

Targeting PADI2 as a potential therapeutic strategy against metastasis in oral cancer via suppressing EMT-mediated migration and invasion and CCL3/5-induced angiogenesis.

Journal: Clinical & experimental metastasis

Published: April 02, 2024

Epigenetic modification in radiotherapy and immunotherapy for cancers.

Epigenetic modification in radiotherapy and immunotherapy for cancers.

Journal: Tzu chi medical journal

Published: January 03, 2024

IRAK2, an Immune and Radiation-Response Gene, Correlates with Advanced Disease Features but Predicts Higher Post-Irradiation Local Control in Non-Metastatic and Resected Oral Cancer Patients.

IRAK2, an Immune and Radiation-Response Gene, Correlates with Advanced Disease Features but Predicts Higher Post-Irradiation Local Control in Non-Metastatic and Resected Oral Cancer Patients.

Journal: International journal of molecular sciences

Published: March 20, 2023

IRAK2, an IL1R/TLR Immune Mediator, Enhances Radiosensitivity via Modulating Caspase 8/3-Mediated Apoptosis in Oral Squamous Cell Carcinoma.

IRAK2, an IL1R/TLR Immune Mediator, Enhances Radiosensitivity via Modulating Caspase 8/3-Mediated Apoptosis in Oral Squamous Cell Carcinoma.

Journal: Frontiers in oncology

Published: December 29, 2020

Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma.

Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma.

Journal: Cancer cell international

Published: November 04, 2020

Emerging Challenges of Radiation-Associated Cardiovascular Dysfunction (RACVD) in Modern Radiation Oncology: Clinical Practice, Bench Investigation, and Multidisciplinary Care.

Emerging Challenges of Radiation-Associated Cardiovascular Dysfunction (RACVD) in Modern Radiation Oncology: Clinical Practice, Bench Investigation, and Multidisciplinary Care.

Journal: Frontiers in cardiovascular medicine

Published: December 15, 2019

c-Myc Acts as a Competing Endogenous RNA to Sponge miR-34a, in the Upregulation of CD44, in Urothelial Carcinoma.

c-Myc Acts as a Competing Endogenous RNA to Sponge miR-34a, in the Upregulation of CD44, in Urothelial Carcinoma.

Journal: Cancers

Published: September 22, 2019

E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.

E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.

Journal: Cancer science

Published: September 27, 2018

ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.

ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.

Journal: Cancer science

Published: September 09, 2018

Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways.

Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways.

Journal: Cancer letters

Published: June 02, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026